Research Analysts Issue Forecasts for Opthea FY2025 Earnings

Opthea Limited (NASDAQ:OPT) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Opthea in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.44) for the year, up from their prior estimate of ($1.60). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Opthea’s FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.24 EPS.

A number of other research firms also recently issued reports on OPT. Oppenheimer downgraded shares of Opthea from an “outperform” rating to a “market perform” rating in a research report on Monday. Canaccord Genuity Group upgraded shares of Opthea to a “strong-buy” rating in a report on Tuesday, December 17th. Leerink Partners cut shares of Opthea from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $12.00 to $1.00 in a research note on Tuesday. Jefferies Financial Group reiterated an “underperform” rating and set a $1.00 target price (down previously from $8.00) on shares of Opthea in a research report on Tuesday. Finally, Leerink Partnrs lowered Opthea from a “strong-buy” rating to a “hold” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $1.33.

Opthea Stock Up 7.2 %

Shares of OPT opened at $3.41 on Thursday. The stock’s fifty day simple moving average is $4.42 and its 200-day simple moving average is $4.07. Opthea has a 12-month low of $1.79 and a 12-month high of $6.30.

Institutional Investors Weigh In On Opthea

Large investors have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new position in shares of Opthea in the 4th quarter valued at $79,000. Hsbc Holdings PLC bought a new position in Opthea during the fourth quarter worth about $556,000. OLD Mission Capital LLC acquired a new position in Opthea in the fourth quarter valued at about $42,000. ABC Arbitrage SA bought a new stake in shares of Opthea in the fourth quarter worth about $40,000. Finally, Twin Lakes Capital Management LLC acquired a new stake in shares of Opthea during the third quarter worth about $81,000. Institutional investors own 55.95% of the company’s stock.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.